PITTSBURGH, March 16, 2006 – PPG Industries is entering the field of azide chemistry with today's announcement that Roche has selected the company to perform a key process step in the manufacture of the active ingredient for Tamiflu® antiviral pharmaceutical.
PPG is one of several companies that will collaborate in the production of the Roche product that prevents influenza from spreading inside the body.
"We're delighted that Roche has selected PPG to manufacture an intermediate for this important antiviral," said Luke Scrivanich, general manager of PPG's fine chemicals business. "PPG is proud to play a significant role in producing a pharmaceutical that addresses a serious world health concern."
Scrivanich said PPG's entry into azide chemistry is a natural extension of the company's expertise in the manufacture of pharmaceutical active ingredients and intermediates.
"Our work with Roche for Tamiflu is a wonderful way to introduce our azide chemistry capabilities," Scrivanich said. "We're excited to be able to offer pharmaceutical companies a greater array of technologies, enabling them to deliver their breakthrough therapies to the global marketplace."
Pittsburgh-based PPG is a world leader in the supply of phosgene derivatives, advanced pharmaceutical intermediates and active pharmaceutical ingredients, with strong emphasis on custom synthesis and manufacturing. PPG is also a global supplier of coatings, glass, fiber glass and industrial chemicals. Sales in 2005 were $10.2 billion.
—22819—Tamiflu is a trademark of Hoffmann-La Roche.